Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia

L. Frattola, R. Piolti, S. Bassi, M. G. Albizzati, G. Galetti, B. Grumelli, N. Canal, M. A. Volonte, D. Zerbi, A. Beltramelli, R. Montanini, D. Uccellini, M. Minazzi, I. Piccolo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A multicenter, open, controlled study was carried out in 126 patients with multi-infarct dementia (MID) of mild to moderate degree. The patients were randomly assigned to balanced blocks in each center and treated for 90 days either with choline alfoscerate (α-GPC) or cytidine diphosphocholine (CDP-choline), one 1-gm vial/day, intramuscularly. Treatments were started after a two-week washout period for any other drugs that had been given for the same purpose. At the baseline check-up and after 45 (T1) and 90 (T2) days of treatment, the Sandoz Clinical Assessment for Geriatric Patients (SCAG), the Modified Parkside Behavior Rating Scale (PBRSM), the memory logic test of the Wechsler Memory Scale, and the word fluency test were used to evaluate the patients. The data were analyzed statistically by parametric and nonparametric tests, as applicable. One hundred seventeen patients completed the study and nine (five in the CDP-choline group and four in the α-GPC group) dropped out for reasons not related to taking the drug. The results indicated that both drugs had positive effects on the memory, cognitive, and behavioral parameters evaluated over the three months, reflecting overall improvement of the clinical pictures of the patients. The effects of α-GPC appeared significantly earlier and were more complete for the SCAG (total score and scores of some clusters) and for the word fluency test. There were no important adverse reactions and neither laboratory parameters nor clinical vital signs were significantly altered.

Original languageEnglish
Pages (from-to)683-693
Number of pages11
JournalCurrent Therapeutic Research
Volume49
Issue number4
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Glycerylphosphorylcholine
Multi-Infarct Dementia
Cytidine
Geriatric Assessment
Therapeutics
Pharmaceutical Preparations
Wechsler Scales
Vital Signs

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Frattola, L., Piolti, R., Bassi, S., Albizzati, M. G., Galetti, G., Grumelli, B., ... Piccolo, I. (1991). Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Current Therapeutic Research, 49(4), 683-693.

Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. / Frattola, L.; Piolti, R.; Bassi, S.; Albizzati, M. G.; Galetti, G.; Grumelli, B.; Canal, N.; Volonte, M. A.; Zerbi, D.; Beltramelli, A.; Montanini, R.; Uccellini, D.; Minazzi, M.; Piccolo, I.

In: Current Therapeutic Research, Vol. 49, No. 4, 1991, p. 683-693.

Research output: Contribution to journalArticle

Frattola, L, Piolti, R, Bassi, S, Albizzati, MG, Galetti, G, Grumelli, B, Canal, N, Volonte, MA, Zerbi, D, Beltramelli, A, Montanini, R, Uccellini, D, Minazzi, M & Piccolo, I 1991, 'Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia', Current Therapeutic Research, vol. 49, no. 4, pp. 683-693.
Frattola, L. ; Piolti, R. ; Bassi, S. ; Albizzati, M. G. ; Galetti, G. ; Grumelli, B. ; Canal, N. ; Volonte, M. A. ; Zerbi, D. ; Beltramelli, A. ; Montanini, R. ; Uccellini, D. ; Minazzi, M. ; Piccolo, I. / Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. In: Current Therapeutic Research. 1991 ; Vol. 49, No. 4. pp. 683-693.
@article{d0f18ac662b645bab7f84a8560af2bc1,
title = "Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia",
abstract = "A multicenter, open, controlled study was carried out in 126 patients with multi-infarct dementia (MID) of mild to moderate degree. The patients were randomly assigned to balanced blocks in each center and treated for 90 days either with choline alfoscerate (α-GPC) or cytidine diphosphocholine (CDP-choline), one 1-gm vial/day, intramuscularly. Treatments were started after a two-week washout period for any other drugs that had been given for the same purpose. At the baseline check-up and after 45 (T1) and 90 (T2) days of treatment, the Sandoz Clinical Assessment for Geriatric Patients (SCAG), the Modified Parkside Behavior Rating Scale (PBRSM), the memory logic test of the Wechsler Memory Scale, and the word fluency test were used to evaluate the patients. The data were analyzed statistically by parametric and nonparametric tests, as applicable. One hundred seventeen patients completed the study and nine (five in the CDP-choline group and four in the α-GPC group) dropped out for reasons not related to taking the drug. The results indicated that both drugs had positive effects on the memory, cognitive, and behavioral parameters evaluated over the three months, reflecting overall improvement of the clinical pictures of the patients. The effects of α-GPC appeared significantly earlier and were more complete for the SCAG (total score and scores of some clusters) and for the word fluency test. There were no important adverse reactions and neither laboratory parameters nor clinical vital signs were significantly altered.",
author = "L. Frattola and R. Piolti and S. Bassi and Albizzati, {M. G.} and G. Galetti and B. Grumelli and N. Canal and Volonte, {M. A.} and D. Zerbi and A. Beltramelli and R. Montanini and D. Uccellini and M. Minazzi and I. Piccolo",
year = "1991",
language = "English",
volume = "49",
pages = "683--693",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia

AU - Frattola, L.

AU - Piolti, R.

AU - Bassi, S.

AU - Albizzati, M. G.

AU - Galetti, G.

AU - Grumelli, B.

AU - Canal, N.

AU - Volonte, M. A.

AU - Zerbi, D.

AU - Beltramelli, A.

AU - Montanini, R.

AU - Uccellini, D.

AU - Minazzi, M.

AU - Piccolo, I.

PY - 1991

Y1 - 1991

N2 - A multicenter, open, controlled study was carried out in 126 patients with multi-infarct dementia (MID) of mild to moderate degree. The patients were randomly assigned to balanced blocks in each center and treated for 90 days either with choline alfoscerate (α-GPC) or cytidine diphosphocholine (CDP-choline), one 1-gm vial/day, intramuscularly. Treatments were started after a two-week washout period for any other drugs that had been given for the same purpose. At the baseline check-up and after 45 (T1) and 90 (T2) days of treatment, the Sandoz Clinical Assessment for Geriatric Patients (SCAG), the Modified Parkside Behavior Rating Scale (PBRSM), the memory logic test of the Wechsler Memory Scale, and the word fluency test were used to evaluate the patients. The data were analyzed statistically by parametric and nonparametric tests, as applicable. One hundred seventeen patients completed the study and nine (five in the CDP-choline group and four in the α-GPC group) dropped out for reasons not related to taking the drug. The results indicated that both drugs had positive effects on the memory, cognitive, and behavioral parameters evaluated over the three months, reflecting overall improvement of the clinical pictures of the patients. The effects of α-GPC appeared significantly earlier and were more complete for the SCAG (total score and scores of some clusters) and for the word fluency test. There were no important adverse reactions and neither laboratory parameters nor clinical vital signs were significantly altered.

AB - A multicenter, open, controlled study was carried out in 126 patients with multi-infarct dementia (MID) of mild to moderate degree. The patients were randomly assigned to balanced blocks in each center and treated for 90 days either with choline alfoscerate (α-GPC) or cytidine diphosphocholine (CDP-choline), one 1-gm vial/day, intramuscularly. Treatments were started after a two-week washout period for any other drugs that had been given for the same purpose. At the baseline check-up and after 45 (T1) and 90 (T2) days of treatment, the Sandoz Clinical Assessment for Geriatric Patients (SCAG), the Modified Parkside Behavior Rating Scale (PBRSM), the memory logic test of the Wechsler Memory Scale, and the word fluency test were used to evaluate the patients. The data were analyzed statistically by parametric and nonparametric tests, as applicable. One hundred seventeen patients completed the study and nine (five in the CDP-choline group and four in the α-GPC group) dropped out for reasons not related to taking the drug. The results indicated that both drugs had positive effects on the memory, cognitive, and behavioral parameters evaluated over the three months, reflecting overall improvement of the clinical pictures of the patients. The effects of α-GPC appeared significantly earlier and were more complete for the SCAG (total score and scores of some clusters) and for the word fluency test. There were no important adverse reactions and neither laboratory parameters nor clinical vital signs were significantly altered.

UR - http://www.scopus.com/inward/record.url?scp=0025806005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025806005&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 683

EP - 693

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 4

ER -